Korsana Biosciences Debuts on Nasdaq After Completing Merger and $380 Million Private Placement

Korsana Biosciences, Inc. has completed its merger with Cyclerion Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on September 9, 2026, under the ticker symbol “KRSA.” The combined company also raised $380 million in a private placement, providing a funded runway for its lead asset.